¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ I%p#E#[G  
cC4T3]4l '  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© pR"qPSv'  
Trrh`@R  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© k mj m6  
nR7\ o(!  
1.Co-stimulators (or co-stimulating molecules) a5-\=0L~  
MjpJAV/84  
2.NK-kB Al|7Y/  
yShHFlO=  
3.Immunoglobulin superfamily K>[H@|k\k  
q}5A^QX  
4.antigen-presenting cell (APC) mw[4<vfB0a  
L|X5Ru  
5.death domain "b 0cj  
U3}R^W~eb  
6.CCR and CXCR f[b YjIX  
IMza 2  
7.Lectin (or mitogen) (5~C _Y  
D.(G9H  
8.Clusters of differentiation, CD) &>e DCs  
?N*0 S'dY  
9.B7 family +,Az\aT/%  
[.X%:H+  
10.Cytotoxic T lymphocyte, CTL) ` l2q G#  
=[JN'|Q+  
11.IL-15 and IL-15 receptor (IL-15R) hZ<btN .y5  
cO,V8#H  
12.MHC restriction aLi_Hrb9  
-kbm$~P  
13.Affinity-chromatography Y/H^*1  
m>ycN  
14.Cyctosprin A, CsA / w M  
U@MP&sdL  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) rxj@NwAno  
{~fCqP.2  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© br  Z, s  
~AanU1U<  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 !y-2#  
j yRSEk$  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 2BDan^:-Av  
=5~F6to  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ ,|X+/|gm  
6@q[tN7_^  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ]<T8ZA_Y;  
;{f??G  
ÃâÒßѧרҵ£º $[iT~B$  
kt{C7qpD  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ ^mueFw}\  
U`8 |9v  
Ïû»¯ÄÚ¿Æ£º D2</^]3Su  
96pk[5lj{?  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ q|o |/O-{  
=+`j?1  
ѪҺ²¡Ñ§×¨Òµ£º 'B (eMnLg  
hiRR+`L%  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»